Investigating Physiological Responses During Driving as Potential Biomarkers of Cognitive Decline in Seniors Using Decision Tree Ensemble Modeling
Keywords: Alzheimer's Disease, Beta-amyloid, Decision Tree Ensemble, Driving and Alzheimer's, Machine Learning, Physiological Signals, Risk Biomarker Discovery
Abstract: Early identification of individuals at risk for Alzheimer's disease is essential to improve treatment effectiveness. Cerebrospinal fluid analyses and positron emission tomography (PET) scans are commonly used to detect the presence of beta-amyloid and tau, which are associated with an increased risk of conversion to Alzheimer’s disease. However, these biomarker tests are expensive and involve invasive procedures. Researchers are working towards discovering easily measurable biomarkers to detect individuals at risk, but only a few have been identified thus far. There is a need to discover biomarkers that are cost-efficient and non-invasive to test. We propose a machine learning approach for discovering potential risk biomarkers of Alzheimer’s disease through the analysis of physiological responses to the cognitively complex task of driving by using decision tree ensemble techniques. Though driving patterns in early Alzheimer’s have been previously studied, physiological responses of cognitively normal seniors during driving remain unexplored. As a first step, we measure heart rate, electrodermal activity, and temperature responses to several driving events, such as right turns and roundabouts, of seniors with and without elevated PET beta-amyloid levels to explore the relationship between these physiological responses and amyloid level. Data were collected from 26 participants with elevated beta-amyloid and 28 without. We used four machine learning algorithms for classification: Random Forest, Extra Trees, AdaBoost, and XGBoost, and developed a novel methodology to extract significant features from these models. By doing so, we successfully identified five risk biomarkers most influential in differentiating the two groups with and without elevated beta-amyloid.
Track: 6. AI for biomarker discovery and drug design
Registration Id: K5NLRLB3VZ8
Submission Number: 352
Loading